Image

Association Between Screening Behaviors and Lung Cancer Spectrum

Association Between Screening Behaviors and Lung Cancer Spectrum

Recruiting
All
Phase N/A

Powered by AI

Overview

The goal of this observational study is to describe the clinical epidemiological characteristics and disease spectrum distribution of newly diagnosed primary lung cancer patients in a real-world setting. The main questions it aims to answer are:

What is the current status of lung cancer epidemiology, including age, gender, smoking history, and pathological subtype distribution? How do different lung cancer screening behaviors (e.g., overscreening, underscreening, guideline-concordant, and precision screening) influence the capture rate of the "curative time window" (defined as adenocarcinoma in situ (AIS)/minimally invasive adenocarcinoma (MIA) or pure Ground-Glass Nodules (GGNs) stage)? What are the economic costs and cumulative radiation exposure associated with these different screening patterns? Researchers will compare these screening behavior groups to evaluate the efficacy of the "low-age, low-frequency" screening strategy in capturing early-stage lung cancer.

Participants will be asked to:

Provide their medical history and detailed records of pre-diagnosis lung cancer screening (including CT scan history).

Allow researchers to collect and analyze their clinical, pathological, and radiological data from hospital records and medical databases.

Complete a questionnaire regarding their screening history and health-related behaviors.

Eligibility

Inclusion Criteria:

  • Histologically confirmed primary lung cancer within the past year (surgical or biopsy pathology).
  • Patients capable of clearly recalling or providing medical and physical examination history prior to diagnosis.

Exclusion Criteria:

  • Recurrent lung cancer or metastatic lung tumors.
  • Severe lack of critical clinical data (e.g., inability to provide pathological type or stage).
  • Patients with cognitive impairment or severe mental illness who cannot cooperate with the questionnaire.

Study details
    Lung Cancer

NCT07626177

Fudan University

27 June 2026

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.